Ocular Therapeutix™ Expands Its Board of Directors with the Election of Industry Leader W. James O'Shea

BEDFORD, Mass.--(BUSINESS WIRE)--Ocular Therapeutix™, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the development and commercialization of innovative therapies for diseases and conditions of the eye, announced today that W. James O'Shea, former President and Chief Operating Officer of Sepracor Inc., has been elected to Ocular's Board of Directors.

"We are very pleased to announce that Jim is joining our Board. With a more than 40-year tenure in the biopharma industry, Jim has extensive commercial expertise, including sales and marketing on an international scale. We believe his insights will be invaluable as we continue to advance our lead programs and prepare for launch and commercialization," said Amar Sawhney, Ph.D., President and Chief Executive Officer.

For nearly a decade, Mr. O'Shea held leadership positions at Sepracor, Inc. He served as President and Chief Operating Officer, where he was responsible for building the organization's commercial infrastructure and led the successful launch and commercialization of Xepenex® and Lunesta®. He also served as Vice Chairman. Prior to Sepracor, Mr. O'Shea was Senior Vice President of Sales and Marketing and Medical Affairs for Zeneca Pharmaceuticals, a business unit of Astra Zeneca Plc. While at Zeneca, he also held management positions of increasing responsibility in international sales and marketing in the US and UK. Mr. O'Shea is a past Chairman of the National Pharmaceutical Council and serves on the board of directors of BTG Plc, ProStrakan Group Plc, and Trevi Therapeutics, and also is Chairman of Cardiome. Mr. O'Shea is a graduate of Liverpool Lord Byron University. He also received an honors degree in applied physics from the Institute of Physics in London.

Mr. O'Shea stated, "I am delighted to be joining the Ocular board at a key time in the Company's development. With an NDA for DEXTENZA for post-surgical ocular pain having been recently filed with the FDA and two additional programs in late-stage clinical trials for allergic conjunctivitis and glaucoma, Ocular has one of the most advanced R&D pipelines in its sector. I look forward to working with my fellow directors and management to help the company execute its commercial strategy and further enhance its value."

About Ocular Therapeutix, Inc.

Ocular Therapeutix, Inc. (NASDAQ: OCUL) is a biopharmaceutical company focused on the development and commercialization of innovative therapies for diseases and conditions of the eye using its proprietary hydrogel platform technology. Ocular Therapeutix's lead product candidates are in Phase 3 clinical development for post-surgical ocular inflammation and pain and allergic conjunctivitis, and Phase 2 clinical development for glaucoma and inflammatory dry eye disease. The Company is also evaluating sustained-release injectable anti-VEGF drug depots for back-of-the-eye diseases. Ocular Therapeutix's first product, ReSure® Sealant, is FDA-approved to seal corneal incisions following cataract surgery.

Forward Looking Statements

Any statements in this press release about future expectations, plans and prospects for the Company, including statements about the development or potential launch and commercialization of the Company's product candidates, such as the ongoing development and potential utility of OTX-DP for post-surgical ocular pain and allergic conjunctivitis and of OTX-TP for glaucoma, the advancement of the Company's other product candidates, the potential for the Company's sustained release hydrogel depot technology, the Company's plans for or success with regulatory submissions, and other statements containing the words "anticipate," "believe," "estimate," "expect," "intend", "goal," "may", "might," "plan," "predict," "project," "target," "potential," "will," "would," "could," "should," "continue," and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors. Such forward-looking statements involve substantial risks and uncertainties that could cause the Company's clinical development programs, future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, those related to the timing and costs involved in commercializing ReSure® Sealant, the initiation and conduct of clinical trials, availability of data from clinical trials and expectations for regulatory submissions and approvals, the Company's scientific approach and general development progress, the availability or commercial potential of the Company's product candidates, the sufficiency of cash resources and need for additional financing or other actions and other factors discussed in the "Risk Factors" section contained in the Company's quarterly and annual reports on file with the Securities and Exchange Commission. In addition, the forward-looking statements included in this press release represent the Company's views as of the date of this release. The Company anticipates that subsequent events and developments will cause the Company's views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date of this release.


Ocular Therapeutix, Inc.
Brad Smith
Chief Financial Officer
[email protected]
Burns McClellan on behalf of Ocular Therapeutix
Kimberly Minarovich, 212-213-0006
[email protected]
Justin Jackson
[email protected]
Ocular Therapeutix, Inc.
Scott Corning
Vice President of Sales and Marketing
[email protected]x.com